Clinical trials: Recurrent Adenocarcinoma
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Kidney Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Trial name
- NCT00027573
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- 6 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Cancer, Prostate Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084825
- Testing
- Docetaxel, Imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Renal Cell Cancer, Renal Cell Carcinoma
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
This phase I/randomized phase II trial is studying the side effects and best dose of bevacizumab and to see how well it works when given together with or without MEDI-522 in treating patients with unresectable or metastatic…
- Conditions
- Recurrent Renal Cell Cancer, Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00684996
- Testing
- etaracizumab, bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Pain, Prostate Cancer
Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer
RATIONALE: Some drugs used in chemotherapy can reduce the pain experienced by some people with cancer. Combining more than one drug may be more effective at reducing cancer pain.
- Conditions
- Pain, Prostate Cancer, Quality of Life
- Trial name
- NCT00003232
- Testing
- clodronate disodium, mitoxantrone hydrochloride, prednisone
- Where
- 21 sites in Canada
- Volunteers
- 227 people
- Sponsor
- NCIC Clinical Trials Group
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment
Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2.
- Trial name
- NCT00009919
- Testing
- semaxanib
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
A Recurrence Nomogram for Hepatoid Adenocarcinoma of the Stomach
This study aims to develop a nomogram to predict postoperative recurrence of HAS and guide individually tailored surveillance strategies.
- Trial name
- NCT05274464
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Fujian Medical University
Focus on Developing a Deep Learning Model to Predict the Recurrence Risk of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar Resection
Deep Learning Model to Predict the Recurrence of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar Resection
This study aims to develop a deep learning model based on noncontrast CT images to predict the recurrence risk of stage IA invasive lung adenocarcinoma after sub-lobar resection，which can serve as potential tool to assist…
- Trial name
- DL-Rec-ILA (NCT06659601)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder
S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma
This phase II trial is studying how well sorafenib works in treating patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma.
- Conditions
- Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Adenocarcinoma With Squamous Metaplasia of the Gallbladder, Cholangiocarcinoma of the Extrahepatic Bile Duct
- Trial name
- NCT00238212
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
This phase I trial is studying the side effects and best dose of temsirolimus when given together with hormone therapy in treating patients with relapsed prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00512668
- Testing
- leuprolide acetate, goserelin acetate, bicalutamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
Phase II trial to study the effectiveness of capecitabine in treating patients who have persistent or recurrent cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma
- Trial name
- NCT00039442
- Testing
- Capecitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Gynecologic Oncology Group
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed.
- Conditions
- Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma, Central Nervous System Neoplasm, Childhood Clear Cell Sarcoma of Soft Tissue
- Trial name
- NCT02867592
- Testing
- Cabozantinib, Cabozantinib S-malate, Pharmacological Study
- Where
- 142 sites in United States
- Volunteers
- 109 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer
This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00101114
- Testing
- sorafenib tosylate, recombinant interferon alfa-2b, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
This phase I trial studies the side effects and best dose of intraperitoneal paclitaxel when given together with doxorubicin hydrochloride and cisplatin in treating patients with stage III-IV endometrial cancer.
- Conditions
- Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma
- Trial name
- NCT00575952
- Testing
- Cisplatin, Doxorubicin Hydrochloride, Filgrastim
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Gynecologic Oncology Group
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients
This study investigates whether molecular testing can help to predict the risk of endometrial cancer coming back (recurrence) after treatment in patients diagnosed with low risk endometrial cancer and scheduled to have surgery to…
- Trial name
- NCT04604613
- Testing
- Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Hysterectomy
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- M.D. Anderson Cancer Center
Anaplastic Thyroid Cancer, Insular Thyroid Cancer
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer.
- Conditions
- Anaplastic Thyroid Cancer, Insular Thyroid Cancer, Metastatic Parathyroid Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
- Trial name
- NCT00068497
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer, Melanoma (Skin)
Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer
RATIONALE: Biological therapies such as flt3L and CD40-ligand use different ways to stimulate the immune system and stop cancer cells from growing.
- Trial name
- NCT00020540
- Testing
- recombinant CD40-ligand, recombinant flt3 ligand
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Adult Rhabdomyosarcoma, Adult Synovial Sarcoma
Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors
This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Childhood Hepatoblastoma, Childhood Synovial Sarcoma
- Trial name
- NCT00831844
- Testing
- cixutumumab, laboratory biomarker analysis
- Where
- 105 sites in United States, Australia and 1 more
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)